NEWS
FDA Approves Abiraterone for Advanced Prostate Cancer
For the second time in a year, the Food and Drug Administration (FDA) has approved a new treatment for men with advanced prostate cancer who, until recently, have had few effective treatment options.
Last Thursday, the agency approved abiraterone (Zytiga) for the treatment of men with metastatic castration-resistant prostate cancer (meaning the disease progresses despite low levels of tumor-fueling hormones) who are no longer responding to the chemotherapy drug docetaxel. Read more > >
Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer
Age, race/ethnicity, individual breast cancer risk, and history of hysterectomy are factorsIntensity-Modulated Radiation Therapy Use for Breast Cancer Influenced by Reimbursement
Private radiation clinics are more likely than hospital-based outpatient clinics to use the expensive technologyWhole-Genome Sequencing Improves Cancer Diagnoses
For one patient, the approach helped doctors select the most appropriate treatmentResearchers Identify Proteins that Help Hepatitis C Virus Enter Liver Cells
Anticancer drugs impede virus entry, indicating possible new approach for treatment
COMMENTARY
A Conversation with Drs. Maureen Hatch and Kiyohiko Mabuchi on the 25th Anniversary of the Chernobyl Nuclear Disaster
The researchers from NCI's Radiation Epidemiology Branch discuss lessons learned from the Chernobyl accident and research on the health consequences of the accident. Read more > >
A MESSAGE TO READERS
NCI's Fiscal Picture and Grant Support for FY2011
Last week, NCI Director Dr. Harold Varmus e-mailed staff regarding NCI's budget and the challenges ahead for the cancer research community. View the full text of the email online.
IN DEPTH
Chernobyl Tissue Bank Provides a Unique Resource to Researchers
A rare opportunity to study the long-term effects of radiation on large populations
Use and Acceptance of HPV Vaccine Still a Work in Progress
Numerous factors influence vaccine uptake, while studies look to expand use
Design Dilemma: The Debate over Using Placebos in Cancer Clinical Trials
Do new molecularly targeted drugs provide rationale for using placebos in cancer clinical trials?
Featured Clinical Trial: Testing Dose-Dense Paclitaxel for Ovarian and Related Cancers
Will dose-dense regimen improve survival outcomes?
UPDATES
Legislative Update
- State Cancer Legislative Database Update Now Available
Notes
- NCI's Gottesman and Fraumeni Receive Prestigious Honors
- NCI Experts Advise U.S. Embassy Staff in Japan during Fukushima Nuclear Crisis
- NCI's Clinical Assay Development Program Seeks Project Applications
- President's Cancer Panel Report Focuses on Need for Better Understanding of Diverse Populations
- Second Telephone Workshop for Cancer Survivors Addresses Weight Changes
- Registry of Measures for Childhood Obesity Research Available
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
